Public views on the donation and use of human biological samples in biomedical research: a mixed methods study
- Celine Lewis1,
- Margaret Clotworthy2,
- Shona Hilton3,
- Caroline Magee4,
- Mark J Robertson5,
- Lesley J Stubbins6,
- Julie Corfield7
- 1Unit 4D, Genetic Alliance UK, London, UK
- 2Human Focused Testing, Cambridge, UK
- 3CSO Social & Public Health Sciences Unit, Medical Research Council, Glasgow, UK
- 4Confederation of Cancer Biobanks, National Cancer Research Institute, London, UK
- 5Science Policy & Relations, AstraZeneca, Cheshire, UK
- 6GlaxoSmithKline Medicines Research Centre, Hertfordshire, UK
- 7BioCity, Areteva Ltd, Nottingham, UK
- Correspondence to Dr Celine Lewis;
- Received 15 April 2013
- Revised 28 May 2013
- Accepted 25 June 2013
- Published 7 August 2013
Objective A mixed methods study exploring the UK general public's willingness to donate human biosamples (HBSs) for biomedical research.
Setting Cross-sectional focus groups followed by an online survey.
Participants Twelve focus groups (81 participants) selectively sampled to reflect a range of demographic groups; 1110 survey responders recruited through a stratified sampling method with quotas set on sex, age, geographical location, socioeconomic group and ethnicity.
Main outcome measures (1) Identify participants’ willingness to donate HBSs for biomedical research, (2) explore acceptability towards donating different types of HBSs in various settings and (3) explore preferences regarding use and access to HBSs.
Results 87% of survey participants thought donation of HBSs was important and 75% wanted to be asked to donate in general. Responders who self-reported having some or good knowledge of the medical research process were significantly more likely to want to donate (p<0.001). Reasons why focus group participants saw donation as important included: it was a good way of reciprocating for the medical treatment received; it was an important way of developing drugs and treatments; residual tissue would otherwise go to waste and they or their family members might benefit. The most controversial types of HBSs to donate included: brain post mortem (29% would donate), eyes post mortem (35%), embryos (44%), spare eggs (48%) and sperm (58%). Regarding the use of samples, there were concerns over animal research (34%), research conducted outside the UK (35%), and research conducted by pharmaceutical companies (56%), although education and discussion were found to alleviate such concerns.
Conclusions There is a high level of public support and willingness to donate HBSs for biomedical research. Underlying concerns exist regarding the use of certain types of HBSs and conditions under which they are used. Improved education and more controlled forms of consent for sensitive samples may mitigate such concerns.
To explore the UK public's willingness to donate: residual biosamples following a medical procedure, biosamples donated as ‘healthy volunteers’, additional biosamples during surgery and biosamples post mortem for medical research.
The acceptability towards donating different types of biosamples in various settings.
Preferences regarding the use of and access to biosamples.
There is a high level of public support for biomedical research and willingness to donate samples for this purpose.
Those responders who self-reported having some or good knowledge of the medical research process were significantly more likely to want to be asked to donate, supporting the need for public education to improve understanding of the research process and the contribution human biological samples (HBSs) make to this.
Concerns exist regarding the use of certain types of samples, the conditions under which they are used and data security; greater transparency and discussion of the safeguards that exist in research are likely to alleviate some of these concerns. More focused communication may also help address the issue that certain subgroups are under-represented and that certain kinds of tissue are infrequently donated.
Strengths and limitations of this study
This study contributes further to our understanding of the UK public's views regarding the types of HBSs acceptable to donate, under what circumstances and for what research purposes. This study highlights the importance of involving the public in a more transparent dialogue about the use of biosamples to encourage greater public involvement and support for this area.
This study presented participants with a series of hypothetical questions about their willingness to donate biosamples for medical research. Therefore, the findings may not necessarily correlate with actual behaviour.
A gradual shift in the approach to biomedical research has accelerated the use of human biological samples (HBSs) and the establishment of biobanks with associated skills and infrastructure (‘biobanking’) to acquire, preserve and distribute this increasingly valuable resource. Biobanks are important custodians of HBS collections, usually with access to the donors’ deidentified phenotypic and clinical data.1 Samples can comprise human materials of all kinds, including organs, tissues and biofluids, such as blood, and genetic materials, such as DNA. They may be obtained from a variety of donated sources: from healthy volunteers or as residual tissue surplus to diagnostic requirements following a medical procedure, or alternatively retrieved post mortem. Sample collections may be population based or disease specific, originating from a wide range of people with differing demographics, health, behaviours and lifestyles. Moreover, they may be used by a variety of research organisations, including public and private enterprises.
The public's willingness to donate HBSs is essential to ensure the continued provision of samples for research2; hence, numerous studies have been conducted to examine this issue.3–7 These studies have shown that the public is generally positive towards research using donated HBSs4–6 and the majority is in principle willing to donate.3 ,7 Less well known are the public's views regarding the types of HBSs acceptable to donate, under what circumstances and for what research purposes, although some research does exist in these areas. For example, research has shown that the public are generally willing to donate diseased tissue or ‘waste material’ (such as cancerous tissue or placental tissue) for biomedical research; however, donation of eyes, brains, lungs and bone is far more contentious.7–9 Regarding access to tissues, research by publicly funded academic researchers has been shown to cause few concerns, in comparison to research conducted by commercial entities.10–12 These issues are important to address to provide an insight into the key drivers that motivate people to donate or prevent people from donating. Knowledge of these can also help inform biobanking governance and ensure consent procedures and patient information addressing any concerns which the public may have. This is important to help the public understand the need for, and the use of, HBSs in biomedical research as well as to increase transparency and engender trust with the public. This study was conducted to broaden our understanding in these areas. Moreover, the findings are intended to inform a biobanking policy for the Strategic Tissue Repository Alliance Through Unified Methods (STRATUM), a UK Government Technology Strategy Board and Industry-funded project seeking to address the problem that there are insufficient numbers of HBSs and associated clinical data of adequate quality to fully support biomedical research in the UK. This research will also help inform the design of new consent templates and deliver guidance and strategies around the consent process for biobanks and researchers.
The aims of this study were to (1) identify participants’ willingness to donate HBSs for biomedical research, (2) explore the acceptability towards donating different types of HBSs in various settings and (3) explore preferences regarding use and access to HBSs. Public views and preferences regarding consent procedures were also investigated and are described in the sister paper related to this study.13
This was a mixed methods study comprising qualitative focus groups and a quantitative online survey. Focus groups were chosen as this method helps people explore and illuminate their views through debate within the group. They can also help facilitate the expression of ideas that might be left underdeveloped in an interview.14 Focus groups have been used successfully to study the attitudes of the general public in relation to biobanking in previous research.15 ,16 A more detailed presentation of the methods can be found in the paper related to this study.13
Twelve focus groups (including one pilot group) were conducted between May and July 2012 in six different geographical locations across the UK. Participants were recruited face to face in the street by the market research company, The Focus Group. Participants were purposively sampled; each group was chosen to reflect a particular demographic (age, socioeconomic group (SEG), ethnicity, ‘patients’ who were affected by a condition or had had an operation in the past 2 years) in order to gather a wide spectrum of views and enable comparisons across groups. Prior to the day, focus group participants were given an information sheet about the use of biosamples in research so that they would have some background knowledge about the subject matter and to get them thinking about the key issues (see online supplementary appendix I). Focus groups were held in ‘neutral’ locations, such as hotel conference rooms or church halls, facilitated by an experienced facilitator (CL) and digitally recorded.
The topic guide explored participants’ views on: willingness to donate and acceptability of donating different types of HBSs, in what circumstances, for what purposes and to whom (see online supplementary appendix II). Recordings were transcribed and the software package NVivo V.9 (QSR International, Pty Ltd) used to facilitate data analysis. This comprised grouping responses to questions into broad thematic categories, which were then refined through subcodes. Coding was conducted by CL and verified by a second researcher to ensure inter-rater reliability. Any discrepancies were discussed between the two researchers until consensus was reached.
The findings from the focus groups were used to inform development of a quantitative survey used to canvas public opinion on the issues of interest across a representative sample of the UK population (see online supplementary appendix III). Key themes that were discussed or emerged from focus group discussions were reframed as survey questions; in a number of cases, answer options in the survey were informed by focus group discussions (eg, the different types of residual HBS participants were presented, which were raised by focus group participants). The survey was carried out by the market research company Research Now using their online panel community of UK residents. A stratified sampling method was used: quotas were set on sex, age, geographical location, SEG and ethnicity, in line with data provided by the Office of National Statistics (ONS) to ensure that the sample was as representative of the UK population as possible. Within each category, a random sample was selected from the Research Now database containing 451 185 active respondents. We aimed to recruit 1000 responders in total. In order to reduce any online bias in our sample, 100 face-to-face interviews with non-internet users were conducted. An additional ‘boost’ sample of 100 people (not included in the main sample analysis) was also conducted with people from three minority ethnic groups (‘Black’, ‘Chinese’, ‘S. Asian’), so that we could conduct subgroup analysis between the groups. The main survey was then conducted in September 2012. Survey participants were not given the background information sheet about the use of biosamples in research, which was given to all focus group participants. This was done so that the survey responses represented the attitudes of the general public as far as possible. They were, however, given information during the survey to enable them to make informed decisions when answering the survey questions.
The participants’ characteristics are detailed in table 1.
One hundred and eighty-two members of the public who were approached were eligible and 81 people agreed to participate (45% response rate; 48 women and 33 men).
Four thousand six hundred and seven people were invited to take part in the survey; 2014 did not respond, 860 started to complete the survey but did not finish, 102 did not qualify to continue, 521 qualified for the survey but the quota was full and 1110 completed the questionnaire (28% response rate excluding those who did not qualify and where the quota was full). This response rate is comparable to similar studies on this topic.6 Our quota sample was close to but not exactly matching our set targets. For this reason, we carried out weighted as well as unweighted analyses. There was no difference in the conclusions we reached by either method. In this paper, we present the unweighted results (weighted results can be found from the online supplementary appendix IV).
Interest in being asked to donate
We began by providing a brief description of the use of HBSs in biomedical research and then asked survey participants whether, in general, they wanted to be asked to donate. Three quarters (75%) of survey participants wanted to be asked (29% definitely yes and 46% probably yes), 18% did not want to (14% probably not and 4% definitely not) and 7% did not know. When asked how important they thought it was to donate HBSs for biomedical research, 87% said it was either extremely important (50%) or important (37%). Less than 1% of participants (n=5) thought it was not at all important.
Respondents who wanted to be asked to donate HBSs were significantly more likely to be: either not religious or only moderately so (where they did have a religious affiliation, 79.7% vs 59.7%, χ2=36.56(1); p=0.001), from higher SEGs (A–D vs E, 83.8% vs 62.2%, χ2=36.55(1); p<0.001), had tissue removed during a medical or surgical procedure (87.2% vs 73.1%, χ2=27.13(1); p<0.001), had some or good knowledge of the medical research process (84.4% vs 75.1%, χ2=13.04(1); p<0.001), were under 55 years (84% vs 75.1%, χ2=11.56(1); p=0.001), were ‘White’ (81.7% vs 60.9%, χ2=10.9(1); p=0.001), had no religious affiliation (86.4% vs 77.9%, χ2=9.9(1); p=0.002) and had an education level of A-level or equivalent or higher (83.4% vs 76.1%, χ2=7.18(1); p=0.007). Using the boost sample for ethnic minorities, we found that ‘Black’ participants were significantly less likely to want to be asked to donate than ‘White’ participants (53.3% vs 81.7%, χ2=20.12(1); p<0.001). Participants who had a close family member affected by a condition were more willing to be asked to donate than those who had not, although the difference was not quite statistically significant (70.7% vs 63.3%, χ2=3.8(1); p=0.051).
Four independent variables were found to have a significant impact on participants’ interest in being asked to donate tissue as shown in the logistic regression model in table 2. The strongest predictor for wanting to be asked to donate was being from a higher SEG (A–D vs E, OR 3.52, 95% CI 2.19 to 5.66; p<0.001) followed by having had tissue removed during a medical or surgical procedure (OR 2.51, 95% CI 1.65 to 3.84; p=0.001), being either not at all or only moderately religious (OR 2.42, 95% CI 1.31 to 4.47; p=0.005) and having self-reported some or good knowledge of the medical research process (OR 2.01, 95% CI 1.33 to 3.03; p=0.001).
Focus group participants also showed a strong willingness to donate HBSs for biomedical research. Four key reasons were provided
by the participants. First, it was a good way of reciprocating for medical treatment received in the past, second, it was
viewed as an ‘important way of developing drugs and treatments’, and third, that residual tissue, which participants did not
have any strong emotional ties to, would otherwise go to waste. The fourth reason offered was one of personal benefit where
participants themselves or a family member was affected by an illness or disease.
Someone in my family has got Alzheimer's so I'm particularly supportive. (Female, 18–24 focus group)
A minority of focus group participants did raise concerns. These included surgeons taking “liberties or advantage of the fact
that you're out cold,” concerns about data privacy and mistrust of profit-making companies using donated HBSs or the government
regulating their use.
The world's very corrupt, and if something needs to get pushed through, it gets pushed through. (Female, ‘Black’ focus group)
While interest in donating appeared to be high, it was evident that knowledge of the medical research process was low. In the survey, only 4% of respondents self-reported having a ‘good knowledge’ of the research process, 54% said they had ‘some knowledge’ and 42% said they had ‘no knowledge’. Similarly, a number of focus group participants commented that the information leaflet was the first time they had heard anything about the use of donated HBSs in medical research.
Types of HBSs
The majority of survey participants were either definitely or probably willing to donate residual blood (92%), cancerous tissue (90%), fat (89%), skin tissue (88%), bone or cartilage (84%) and liver tissue (84%) following a medical procedure (figure 1). Less than half of the participants were willing to donate spare eggs (women only, 48%) or spare embryos (44%) left over following in vitro fertilisation (IVF).
These results confirm our focus group findings, where most people were willing to donate residual tissue but donation of reproductive
tissue raised concerns for a significant number of participants. A key concern was that reproductive tissue would be used
for reproductive purposes without the knowledge of the donor.
Although they said it's [ethical approval process] very strict, I still in the back of my mind have a thing where someone
could take my egg and have my child. (Female, had operation in past 2 years)
A further concern related to whether it was ‘right’ from an ethical or religious perspective to be conducting research on
I would be really worried...an embryo is a baby. I know it's still very, very early days, but you're playing God. (Female—patient
affected by a condition)
Those people who were willing to donate reproductive tissue underscored the benefits that could result from such research.
You have to remove yourself from the situation and imagine yourself as an infertile person and maybe someone that could benefit
immensely from that research. (Female—18–24 focus group)
Some did, however, highlight the importance of being informed as to how reproductive tissue would be used because of its sensitive nature.
Survey participants were then presented with a scenario in which they were asked to imagine that they are in a hospital waiting room awaiting an appointment and are asked whether they would donate certain types of HBSs specifically for the purposes of medical research (figure 2). Most responders were either definitely or probably willing to donate urine (89%), saliva (89%) and blood (81%); however, fewer people would donate tissue taken during a local anaesthetic (67%) or sperm (men only, 58%).
Focus group participants were also generally positive towards donating HBSs specifically for research purposes, although some
commented that they would not want to undergo an invasive procedure.
Depends on what they wanted, if it's not invasive or nothing then I'd say yes. (Female—‘Black’ focus group)
A number of them said they would be more likely to donate HBSs if they did not have to travel somewhere specifically to do
so. Focus group participants also appeared to want more information about how their sample would be used if they were donating
HBSs as ‘healthy’ volunteers.
I'd want to know the purpose behind it but if I'm helping something then why not? (Male—‘Chinese’ focus group)
Additional HBSs during surgery
Finally, survey participants were presented with a scenario in which they are having surgery which requires a general anaesthetic, and asked whether they would be willing to have additional tissue taken that is not required to be removed for therapeutic benefits. Over three quarters of the responders (78%) were willing to donate HBSs taken from the same part of the body being operated on, 63% were willing to donate HBSs taken from an area close by and 44% would donate HBSs involving an additional procedure, for example, taking bone marrow while under the same general anaesthetic.
This scenario was not explored explicitly with focus group participants, but was included in the survey as a number of them
had aired concerns about surgeons taking additional tissue during surgery without consent.
I would be worried about giving consent before they performed an operation in case the main task of the operation is to remove
cancer...and they take some tissue for research. I think it would be OK but only if they asked. (Male, 18–24 group)
Donation of HBSs in the event of one's death
We explored whether the public were willing to donate tissue and whole organs in the event of their death. First, we compared survey responders’ views concerning the donation of tissue taken from an organ with donating a whole organ using the liver and brain as examples. We found that tissue type had a greater impact on people's willingness to donate than the amount of tissue: 89% of people were willing to donate liver tissue, 68% a whole liver, 66% brain tissue and 53% a whole brain. On presenting participants with a list of organs and asking them whether there were any whole organs they would not consider donating for medical research in the event of their death, 71% said they would not donate their brain, 65% would not donate their eyes, 27% would not donate their heart, 14% would not donate their liver, 14% would not donate their lungs and 13% would not donate their kidneys. Five people (0.5%) said they would not donate reproductive tissue in the free text box. Seventeen per cent would not donate any organs for medical research.
Donating whole organs for medical research in the event of one's death caused unease for a number of focus group participants. Some had concerns about the impact on family members, citing that it was a ‘sensitive subject’ that made them feel ‘uncomfortable’. A woman in the South Asian group cited religious reasons for not wanting to donate organs. Others did not like the idea of their body being ‘chopped up like on a butcher's board’ and preferred ‘to remain whole’ and ‘untouched’. A few participants erroneously believed that their organs would not be useful to researchers because they were old or unhealthy. When focusing on particular organs, eyes were found to be most contentious and made participants feel ‘funny’ or ‘squeamish’. They also had concerns that eyes were ‘identifiable’.
When asked whether they would be willing to donate whole organs not suitable for transplant for research purposes instead, 68% of survey responders said they would, 11% would prefer they were not used at all if they could not be used for transplant, 9% would not agree to donate an organ for transplant and 12% did not know.
Uses of HBSs
The most controversial types of research were research involving HBSs in combination with animals (only 34% of survey participants would donate for this purpose), research conducted outside the UK (35%) and research involving ‘cells from embryos’ (41%; figure 3). Research into understanding how our body fights disease was the least controversial (85%).
Research involving animals was cited as a cause for concern by a number of focus group participants, particularly if the research caused the animals ‘excessive pain’. Others had concerns about the way animals were cared for in research settings. Nevertheless, a view held by a significant number of people was that research and drugs tested on animals was “not a nice thought...but in the long run the best option’ and that ‘the information gained from watching [an animal used in research] might help thousands of people.”
Research conducted outside the UK was a matter of concern for some focus group participants because other countries might not have similarly strict governance arrangements as those that exist in the UK, or because HBSs might be sold. Other types of research cited as being controversial included cloning, stem cell research, genetic engineering and ‘designer babies’.
Access to HBSs
Most survey responders were willing to donate HBSs to National Health Service (NHS) hospitals (84%), medical research charities (79%), universities (68%), diagnostic companies (63%) and pharmaceutical companies (56%; figure 4).
Focus group discussions highlighted that there was generally a high level of faith in the benefits of science, and trust towards
the NHS, charities and universities, who were seen as contributing positively towards society. The role of ethics review boards
and legal systems in providing oversight and control of medical research was considered important; nevertheless, it was acknowledged
that most people are unaware of these safeguards.
I do now know something about the process, and like the ethics side and presenting to a board, but before I wouldn't have
known anything about the research process. So I guess I'm just thinking, how would I feel if I didn't know about those procedures?
Some initial negativity was found in relation to pharmaceutical companies conducting research because of their commercial, profit-making nature and concerns that they ‘exploit patients’. However, such concerns were often addressed by other members of the group who acknowledged that commercialisation of research was ‘a fact of life’ and that pharmaceutical companies ‘need to make money to keep their research going’.
Medical records and lifestyle information
We asked participants whether they would be willing to have medical records and lifestyle information linked but deidentified (so that the sample is anonymous to the researcher but contains codes that would allow others to identify an individual from it) to their biosample. Sixty-eight per cent of survey responders would, 22% would not and 10% did not know. Survey responders were more willing to have their deidentified lifestyle information linked to their biosample; 82% would, 12% would not and 6% did not know.
Concerns about linking medical records with HBSs were raised by focus group participants. Data protection and privacy were
two key concerns; for example, participants were worried that their personal data might be ‘hacked or mislaid’. Others cited
concerns about data being accessed by the police or insurance companies. Some participants felt uncomfortable about sensitive
medical details such as sexual diseases or illegal drug use being seen by people unconnected with their health. Nevertheless,
most participants understood the importance of linking medical records and lifestyle information to HBSs as long as they were
You want the sample to be as useful as possible so you want to give them the most complete picture. You want to give them
all the information that is available. (Male—had operation in past 2 years)
Results from this study are consistent with the findings from other empirical research that there is a high level of public support for biomedical research and willingness to donate HBSs for this purpose.3–5 ,7 ,17–19 However, by presenting participants with scenarios consisting of a variety of HBS types across a number of settings, and by using qualitative as well as quantitative methods, we have been able to build a richer understanding of public attitudes. While it is important to bear in mind that the opinions expressed are hypothetical and therefore do not necessarily correspond with how people would actually behave in practice, they still offer an intriguing insight into public attitudes which can help inform policy and practice.
The general willingness of the UK public to donate residual HBSs is consistent with findings from other studies conducted in the UK, the USA and Scandinavia where willingness to donate varied from 67% to 88%.3–5 ,7 ,17 ,18 Interestingly, people who themselves had had tissue removed were significantly more likely to want to be asked to donate than those that had not (87% compared to 73%). A number of other studies conducted in the UK and elsewhere have found patients’ willingness to be high, between 83% and 99%.20–25 This is likely to be so because donation of surplus tissue provides patients with an opportunity to reciprocate or demonstrate gratitude towards those involved in the therapeutic process22 or because they have had the medical need explained to them and can relate to the experience more closely. Those responders who self-reported having some or good knowledge of the medical research process were also significantly more likely to want to be asked to donate. This finding supports the need for public education to improve understanding of the research process and the contribution made to this by HBSs. We identified that more people saw a biosample donation as important (87%) than wanted to be asked to donate (75%). It may be that although people see a donation as important, other concerns, for example, around issues such as data privacy, or other ethical considerations, such as commercial use of HBSs, may prevent some people from donating; concerns have been identified in this and other empirical studies.5 ,16 ,20 ,26
Lower levels of support for HBSs donation were identified among minority ethnic groups, a finding that has been seen elsewhere, particularly among African-Americans19 ,27–29 and Asian-American women.30 A study conducted in China also found that the public and patients’ willingness to donate residual tissue was low compared to studies conducted in the UK, Scandinavia and the USA, at only 65%.31 These differences may stem from different cultural attitudes towards donation, religious beliefs or low levels of trust in public institutions (which may stem from previous breaches of trust as highlighted by Ma et al31 among the ‘Chinese’ population). Mistrust of profit-making companies and the government was identified during focus group discussions with ethnic minority groups in this study, although not exclusively so. Information about the role of ethics review boards in safeguarding participants’ interests is therefore vital for ensuring public trust.
A large proportion of people were unwilling to donate reproductive tissue. This type of HBSs donation raised a number of unique moral, ethical and social concerns, as exemplified by focus group discussions. Interestingly, the survey showed that men were more likely to donate semen than women were likely to donate excess eggs following an IVF procedure (58% vs 48%), which may indicate that egg donation is a more contentious issue or that women feel a greater attachment to eggs than men to sperm.32 Another possible reason may be the limited number of eggs that a woman has, and the greater effort and risk required to make them available ex vivo, resulting in a more judicious approach to their use; for example, women may prefer to keep excess eggs following IVF for future uses rather than donate them for research. More controlled forms of consent (tiered or specific) may be one way of alleviating concerns people may have about donating sensitive HBSs.
When asked to consider post mortem donation, eyes and brains were considered the least desirable organs to donate for research purposes, a finding that has been reported elsewhere.7 As the donation of eyes is crucial for vision research and drug testing, and with donated brains being essential for research into conditions such as multiple sclerosis, Alzheimer's and Parkinson's disease, different ways of raising awareness and motivating donation need to be considered. For example, completely transparent discussion with families on the day prior to forensic post mortem examination, conducted in a sensitive manner, has led to research authorisation and donation in a very high proportion of cases to the Sudden Death Brain and Tissue Bank in Edinburgh.33 It may also be worth considering incentives to donation for research, as have already been discussed in depth elsewhere, although with a greater emphasis on donation for transplant.34 Our research highlights that a significant number of people (68%) would be willing to donate whole organs not suitable for transplant for research purposes instead. Such soft incentives are likely to be welcomed by families, a finding which has also been reported by Womack and Jack35 where over 70% of family members consented to the retrieval of blood and tissue at the time of post mortem examination.
The finding that 67% of people were willing to undergo a local anaesthetic to donate tissue seems unusually high at first glance. Nevertheless, such a finding should not be dismissed; women have been known to undergo local aesthetic to donate healthy breast tissue for breast cancer research, as evidenced by the 2800 women who have donated to the Komen Tissue Bank in the USA.36 The finding that a significant proportion of the public are willing to donate as ‘healthy volunteers’ also supports the premise that there is a strong altruistic desire to contribute to medical research and a high level of trust in and support for the research process.8
Research involving animals and research conducted outside the UK were the least supported research types in this study. Animal research remains a controversial topic and much empirical and ethical debate has focused on this issue.37–39 However, the finding that a large proportion of the public do not want their HBSs used for research outside the UK is intriguing. Our qualitative data show that concerns exist around regulation and commodification of HBSs, findings supported elsewhere in the literature.40 ,41 To address these concerns, potential donors should be provided with information related to the specific issues that relate to those countries where HBSs are likely to be sent.
Regarding access to donated HBSs, the overall findings indicate high levels of trust towards research organisations conducting biomedical research. The lowest trust was afforded to pharmaceutical companies, primarily because of their profit-making nature, a finding which concurs with other studies.5 ,10 ,11 Greater transparency and education of the public by the research community about the role pharmaceutical companies play in research and drug development, (as is currently being conducted through initiatives such as EUPATI; http://www.patientsacademy.eu), will help to highlight the collaborations that frequently exist between private and public enterprises. Emphasising the safeguards that exist in research through regulation and ethics review boards is also likely to alleviate some of these concerns.
Finally, our research reinforces the concerns held by the public regarding the linking of deidentified clinical data to HBSs.20 ,26 Discussion during the consent procedure around the value of associated clinical data, and the safeguards in place to ensure data security, may go some way to reducing these worries. Similarly, the strict governance arrangements around access to personal information by third parties, including the police, insurance companies and employers, should be made clear.
Strengths and limitations
As with any qualitative research, the findings from this study rely on the researcher's interpretation of comments made by focus group participants. Nevertheless, we have used a methodology grounded in the data and ensured inter-rater reliability through cross-checking coding to ensure that the interpretation was as close to the intended meaning as possible. Moreover, we have been able to verify focus group findings through the results from the survey. A major limitation of this study is its hypothetical nature; hence, the results need to be interpreted with caution. Nevertheless, where possible, we presented questions as scenarios to try and make them as ‘real’ as possible. We also provided focus group participants with a background information sheet so that they had some knowledge about the subject matter before the discussion took place and, as such, were likely to be more well informed than the general public. Survey participants were not given this information sheet and were only given selective background information that it was felt (by the authors) was necessary to enable them to make informed decisions when answering questions. This in itself, however, may have impacted the representativeness of the findings as they may have responded differently if no background information had been provided. A further limitation is that the dropout rate was relatively high; participants who did complete the survey may have done so because of a strong attachment to the issues raised and this may have skewed the results. However, every effort was made to ensure that the results were as representative of the UK population as possible. Finally, the focus groups and survey were conducted in English, which excluded those people who were not competent English speakers and/or readers. Our findings are therefore not necessarily representative of the non-English speaking community living in the UK.
There is a high level of public support for, and willingness to contribute to, biobanking and the research process. In particular, people appear to be keen to contribute to research above and beyond the donation of residual tissue. Nevertheless, underlying concerns exist regarding the use of certain types of HBSs, the conditions under which they are used and data security, although these issues did not necessarily preclude the willingness to participate. Improved public education in these areas, for example, through the development of a ‘Frequently Asked Questions’ document which includes information on the ethics infrastructure that exists in the UK may mitigate some of these concerns. More controlled forms of consent and focused communication for sensitive types of HBSs may also positively impact the public's willingness to donate infrequently donated tissue types. More focused communication may also address the finding that certain subgroups, such as particular minority ethnic groups, are less likely to donate. Finally, greater transparency in the biomedical research process and the fostering of trust in those organisations involved throughout that process is vital to ensure that the process of donating tissue to biobanks is satisfactory to all parties involved. These suggestions should be considered by the research community and policy makers.
The authors would like to thank Lisa Bennett, Sarah Dickson, Catherine Elliott, James Ironside and Chris Womack for their helpful comments on this manuscript; Sarah Dickson, Jim Elliott and the late Neil Formstone for their contribution to the design of the study and development of the focus group and survey questions; and Samantha Reeve and Zheng Lei for helping with data analysis. Focus group recruitment was conducted by the company The Focus Group and the survey was conducted through the market research company Research Now.
Contributors JC conceived the study. All authors contributed to the study design and development of the focus group and survey questions. CL facilitated the focus groups and conducted data analysis and interpretation with the help of Samantha Reeve and Zheng Lei. The initial draft of the manuscript was prepared by CL and then circulated repeatedly among the authors for critical revision. All authors approved the final version of the manuscript.
Funding This work was supported by a grant from the Technology Strategy Board through the Stratified Medicines Competition grant number 101021; direct financial contributions were made by AstraZeneca and resources in kind by AstraZeneca, GlaxoSmithKline and Lab 21.
Competing interests LJS is an employee of GlaxoSmithKline. MJR is an employee of AstraZeneca.
Ethics approval This study was approved by the Ethics Review Board of the University of Manchester, reference 11459.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Transcripts from the focus groups and full results of the survey are available from CL at firstname.lastname@example.org. Supplementary material is also available at http://www.geneticalliance.org.uk/projects/stratum_docs.htm
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/